Skip to content

Kailera Therapeutics, Inc.

KLRA

CIK 0002096997

← back to feed
Revenue (TTM)
—
Q1 May 2026
Net Income (TTM)
—
Q1 May 2026
EPS Diluted (TTM)
—
Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
—
Q1 May 2026
Net Margin
—
Q1 May 2026
Free Cash Flow (TTM)
—
Q1 May 2026
Cash
$111.83M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
129.57M sh
Q1 May 2026

Recent filings